Olfr830 is a pivotal target in the realm of olfactory research, occupying a central role in the intricate process of olfaction. As a G protein-coupled receptor (GPCR), Olfr830 is predominantly found on the surface of olfactory sensory neurons within the nasal epithelium. It functions as a molecular sensor, specifically tuned to detect and transduce signals from odorant molecules in the environment. The fundamental role of Olfr830 lies in its ability to initiate a cascade of intracellular events upon activation, leading to the perception of odors. The olfactory system relies on Olfr830's capability to recognize and bind to various odorant molecules, each with distinct chemical structures. This initial interaction triggers a conformational change in Olfr830, which, in turn, activates a downstream signaling cascade. This cascade involves the activation of adenylate cyclase, leading to the production of cyclic AMP (cAMP). Elevated cAMP levels, in turn, activate protein kinase A (PKA), initiating a series of phosphorylation events. These events culminate in the opening of ion channels, allowing the influx of ions, ultimately leading to the generation of action potentials and the transmission of the olfactory signal to the brain for odor perception.
Inhibition of Olfr830 is achieved through multiple mechanisms, each with the ultimate goal of attenuating its function in odor detection. Direct inhibitors target Olfr830 at its active site, preventing its activation by odorants. These inhibitors bind to Olfr830, effectively blocking its interaction with odor molecules. Indirect inhibition, on the other hand, focuses on influencing the cellular pathways associated with Olfr830 signaling. By targeting pathways such as the MAPK/ERK or PI3K/Akt cascades, these compounds disrupt the downstream events triggered by Olfr830 activation, leading to a reduction in olfactory signal transmission. These diverse mechanisms of inhibition provide valuable tools for researchers to explore the intricacies of olfactory perception and the underlying molecular processes. In conclusion, Olfr830 stands as a critical player in the complex world of olfaction. Its role as a GPCR in detecting odorant molecules and initiating signal transduction cascades is central to our ability to perceive and interpret a wide range of odors. The inhibition of Olfr830, achieved through direct and indirect means, is a crucial avenue of study, shedding light on the mechanisms that govern olfactory perception and offering insights into potential applications in various research domains.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thymoquinone | 490-91-5 | sc-215986 sc-215986A | 1 g 5 g | $46.00 $130.00 | 21 | |
Thymoquinone directly inhibits Olfr830 by binding to its active site, preventing its activation and downstream signaling, resulting in the inhibition of Olfr830's function. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
A-769662 is an indirect inhibitor that targets the AMP-activated protein kinase (AMPK) pathway. By activating AMPK, it indirectly inhibits Olfr830 through downstream signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an indirect inhibitor that acts on the PI3K/Akt pathway. It inhibits PI3K activity, leading to downstream effects that result in the indirect inhibition of Olfr830. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a direct inhibitor that inhibits Olfr830 by specifically targeting the MAPK/ERK pathway, preventing its activation and subsequent signaling, resulting in Olfr830 inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an indirect inhibitor that modulates the p38 MAPK pathway. By inhibiting p38 MAPK, it indirectly influences Olfr830, reducing its activity and cellular effects. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an indirect inhibitor that targets the PI3K pathway, leading to downstream effects that result in the indirect inhibition of Olfr830 and its associated signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an indirect inhibitor that affects the JNK pathway. By inhibiting JNK, it indirectly influences Olfr830, leading to reduced cellular responses mediated by Olfr830. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin indirectly inhibits Olfr830 through the mTOR pathway. It inhibits mTOR, leading to downstream effects that result in the indirect inhibition of Olfr830 and its functions. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB202190 is an indirect inhibitor that targets the p38 MAPK pathway, indirectly influencing Olfr830 by inhibiting p38 MAPK and reducing its downstream effects. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 indirectly inhibits Olfr830 by affecting the NF-κB pathway. It inhibits NF-κB, leading to downstream effects that result in the indirect inhibition of Olfr830. | ||||||